These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 30261606)

  • 21. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug delivery: beyond active tumour targeting.
    Sagnella SM; McCarroll JA; Kavallaris M
    Nanomedicine; 2014 Aug; 10(6):1131-7. PubMed ID: 24823644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical role of the TME in solid cancer.
    Giraldo NA; Sanchez-Salas R; Peske JD; Vano Y; Becht E; Petitprez F; Validire P; Ingels A; Cathelineau X; Fridman WH; Sautès-Fridman C
    Br J Cancer; 2019 Jan; 120(1):45-53. PubMed ID: 30413828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition.
    Moloney C; Roy Chaudhuri T; Spernyak JA; Straubinger RM; Brougham DF
    Acta Biomater; 2023 Mar; 158():611-624. PubMed ID: 36603732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.
    Mu Y; Zhang Z; Zhou H; Ma L; Wang DA
    Biomater Sci; 2024 Aug; 12(16):4045-4064. PubMed ID: 38993162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor targeting using liposomal antineoplastic drugs.
    Huwyler J; Drewe J; Krähenbuhl S
    Int J Nanomedicine; 2008; 3(1):21-9. PubMed ID: 18488413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complex interplay between tumor microenvironment and cancer therapy.
    Shen M; Kang Y
    Front Med; 2018 Aug; 12(4):426-439. PubMed ID: 30097962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
    Lucas AT; Madden AJ; Zamboni WC
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1419-33. PubMed ID: 26173794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity.
    Luo X; Liu M; Hu L; Qiu Q; Liu X; Li C; Lu M; Liu Y; Zhang T; Zhou S; McClements DJ; Jia X; Deng Y; Song Y
    Int J Pharm; 2018 Aug; 547(1-2):315-329. PubMed ID: 29886095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposomal drug formulations in cancer therapy: 15 years along the road.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The interactions of paclitaxel with tumour microenvironment.
    Yu DL; Lou ZP; Ma FY; Najafi M
    Int Immunopharmacol; 2022 Apr; 105():108555. PubMed ID: 35121223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.
    Fens MH; Hill KJ; Issa J; Ashton SE; Westwood FR; Blakey DC; Storm G; Ryan AJ; Schiffelers RM
    Br J Cancer; 2008 Oct; 99(8):1256-64. PubMed ID: 18797467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence.
    Song C; Phuengkham H; Kim YS; Dinh VV; Lee I; Shin IW; Shin HS; Jin SM; Um SH; Lee H; Hong KS; Jin SM; Lee E; Kang TH; Park YM; Lim YT
    Nat Commun; 2019 Aug; 10(1):3745. PubMed ID: 31431623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles.
    Rodallec A; Sicard G; Fanciullino R; Benzekry S; Lacarelle B; Milano G; Ciccolini J
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1139-1147. PubMed ID: 30354685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy.
    Moosavian SA; Bianconi V; Pirro M; Sahebkar A
    Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoparticle mediated cancer immunotherapy.
    Gupta J; Safdari HA; Hoque M
    Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors.
    Dicheva BM; Koning GA
    Expert Opin Drug Deliv; 2014 Jan; 11(1):83-100. PubMed ID: 24320104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
    Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
    Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.